Peter Johannes Holst

7PUBLICATIONS
36CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsMolecular targetsInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Agricultural molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 26, 2024
Cancer Vaccines: Recent Insights and Future Directions.

Aretia-Teodora Malacopol, Peter Johannes Holst

|Jun 28, 2023
Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice.

Isabella Skandorff, Emeline Ragonnaud, Jasmin Gille

|Dec 19, 2022
Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 Cancers in Mice.

Ditte Rahbæk Boilesen, Patrick Neckermann, Torsten Willert

|Feb 15, 2022
GPR183 Is Dispensable for B1 Cell Accumulation and Function, but Affects B2 Cell Abundance, in the Omentum and Peritoneal Cavity.

Line Barington, Liv von Voss Christensen, Kristian Kåber Pedersen

|Jul 12, 2020
Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based Immunotherapy.

Amaia Vergara Bermejo, Emeline Ragonnaud, Joana Daradoumis

|Jun 20, 2020
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.

Ilaria Esposito, Paola Cicconi, Anna Morena D'Alise

Pageof 2

Frequent Collaborators

2 joint publications

Jan Pravsgaard Christensen

2 joint publications

Mariano Stornaiuolo

1 joint publications

Amaia Vergara Bermejo

1 joint publications

Joana Daradoumis